Description
Pharmacological class: Integrase strand transfer inhibitor (INSTI) – antiretroviral agent.
Mechanism of action:
Raltegravir inhibits the integrase enzyme, blocking the strand transfer step of retroviral DNA integration into the host genome. This prevents stable infection of host cells and limits viral replication.
Maximum recommended dose:
To be defined according to veterinary prescription and patient-specific protocol.
Dosage frequency:
According to combination therapy protocol and veterinary indication.
Adverse effects:
Adverse effects are based on clinical experience in feline patients and extrapolated data from human medicine.
Raltegravir is generally well tolerated. Reported adverse effects may include mild gastrointestinal signs or transient changes in appetite.
In clinical and field use, no significant adverse effects have been consistently observed when administered at appropriate doses.
Indications:
-
Feline retroviral infections (e.g., FeLV)
-
Reduction of viral replication
-
Use in combination antiretroviral protocols
-
Long-term management strategies
Important:
This product is intended to be used as part of a combination antiretroviral therapy protocol, not as a standalone treatment.
Storage:
-
Store at room temperature
-
Keep away from direct sunlight
Disclaimer:
For veterinary use only.
Use under supervision of a licensed veterinarian.
Availability may vary by country. Please confirm before purchase.
Phoenix does not accept returns, refunds, or exchanges once the purchase has been completed.
